FDA Approves First New Head and Neck Cancer Drug in a Decade
Rybrevant Faspro shrank tumours in 42% of patients whose cancer had returned after chemotherapy and immunotherapy, in a trial of 102 people.
Johnson & Johnson
Read Full News